AriBio Progresses Novel Alzheimer's Contender Despite Mixed Phase II

But Will Benefits Be Enough?

Korea's AriBio is poised to file for US Phase III trial approval this year for its novel Alzheimer's candidate and lead asset AR1001, which showed an improvement in cognitive function from baseline at Phase II. But will the benefits over existing therapies be enough to carve a position in the challenging field?

Alzheimer's Disease
Study Shows Cognitive Improvements In Alzheimer's • Source: Shutterstock

AriBio Co., Ltd. intends to file for approval to begin a Phase III US trial with its first-in-class oral therapy for Alzheimer’s disease AR1001, after Phase II results showed an improvement in cognitive functions from baseline along with safety and tolerability, the South Korean bioventure has said.

Preclinical studies with the molecule have confirmed it acts via multiple novel pharmacological mechanisms, including inhibition of neuronal apoptosis and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.